RESOURCES

cfDNA sample analysis workflow for precision oncology

June 19, 2024

With the market for liquid biopsy analysis of cfDNA mutations growing rapidly, it’s important to describe Adelis’ complementary approach to precision oncology in this infographic.

Adelis’ cfDNA size profiling serves as a quality control step, assessing tumor-derived cfDNA presence while consuming minimal sample. cfDNA profiles can reveal biomarkers for monitoring treatment response, as demonstrated in the SCHISM study for predicting immunotherapy response. Integrating cfDNA and ctDNA biomarkers provides a complementary approach in precision oncology.